Physician profile
Anne E Wilmoth
NPI 1710315569
$3,316.01
in general payments reported to CMS, 2019-2025
27 companies · $804 in 2025
The $804 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,012 · 2022: $30.44 · 2023: $563 · 2024: $907 · 2025: $804.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,273.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $663.22 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $464.47 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $346.99 | 2021-2025 | Otezla, Repatha, Evenity |
| Astrazeneca Pharmaceuticals LP | $319.29 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $251.83 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $233.56 | 2021-2025 | Gardasil 9, Vaxelis, Rotateq |
| Pfizer INC. | $180.87 | 2021-2025 | |
| Glaxosmithkline, LLC. | $177.57 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.43 | 2021-2025 | Jardiance, Synjardy |
| Biohaven Pharmaceuticals, INC. | $84.39 | 2021 | |
| Exact Sciences Corporation | $74.68 | 2023-2025 | Cologuard Collection Kit |
| Currax Pharmaceuticals LLC | $41.08 | 2021-2025 | Contrave, Onzetra Xsail |
| Astellas Pharma US INC | $35.48 | 2021-2024 | Veozah |
| Viatris Specialty LLC | $32.49 | 2025 | Yupelri |
| Xeris Pharmaceuticals, INC. | $31.08 | 2023 | Keveyis |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $30.76 | 2024 | |
| Eisai INC. | $28.74 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $27.92 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.47 | 2021 | |
| Boston Scientific Corporation | $21.29 | 2025 | Watchman Flx |
| Amneal Pharmaceuticals LLC | $21.00 | 2023 | Unithroid |
| Daiichi Sankyo INC. | $16.13 | 2023 | Injectafer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.44 | 2025 | Xifaxan |
| Acadia Pharmaceuticals INC | $15.17 | 2025 | Nuplazid |
| Dexcom, INC. | $15.09 | 2024 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $14.96 | 2024 | Yupelri |
| Abbott Laboratories | $13.61 | 2025 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Wilmoth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.